Collegium Pharmaceutical, Inc. (COLL)

Market Cap	1.06B +12.2%
Revenue (ttm)	780.57M +23.6%
Net Income	62.87M -9.1%
EPS	1.73 -6.6%
Shares Out	31.75M
PE Ratio	19.27
Forward PE	4.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	791,443
Open	33.44
Previous Close	32.76
Day's Range	33.33 - 33.94
52-Week Range	23.23 - 50.79
Beta	0.77
Analysts	Strong Buy
Price Target	51.40 (+53.75%)
Earnings Date	May 7, 2026

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL
• Website: https://www.collegiumpharma.com

Financial Performance

In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.

Analyst Summary

According to 5 analysts, the average rating for COLL stock is "Strong Buy." The 12-month stock price target is $51.4, which is an increase of 53.75% from the latest price.

Price Target

$51.4

(53.75% upside)

Analyst Consensus: Strong Buy